News Quantified

AKBA – akebia therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.

Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

-13.5%

IN-LINE

-23.8%

BEAT

2.3%

BEAT

-10.1%

MISS

Form 8-K Akebia Therapeutics, For: Nov 28

Form 8-K Akebia Therapeutics, For: Nov 12

Form 10-Q Akebia Therapeutics, For: Sep 30

Form 8-K Akebia Therapeutics, For: Nov 10

Form 8-K Akebia Therapeutics, For: Oct 28

Top News Gainers

3/19 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $15.00 price target on the stock. 34.5%

11/22 Form 4 Akebia Therapeutics, For: Nov 20 Filed by: Smith Cynthia 21.7%

3/23 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 16.2%

8/8 Q2/2019 6/30/2019 EPS -0.490 ZacksConsensus -0.350 ActVsEst (0.140) - Miss 13.9%

3/13 Akebia Therapeutics, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates [Yahoo! Finance News] 13.2%

3/10 Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 8.2%

3/23 Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference 6.7%

8/8 Form 10-Q Akebia Therapeutics, For: Jun 30 5.8%

4/23 Form DEF 14A Akebia Therapeutics, For: Jun 05 5.3%

9/9 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock. 5.2%

Top News Decliners

3/15 A Message from Akebia Therapeutics, Inc.’s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic: -14.5%

11/12 Q3/2019 9/30/2019 EPS -0.460 ZacksConsensus -0.370 ActVsEst (0.090) - Miss -14.4%

12/2 Introducing Akebia Therapeutics (NASDAQ:AKBA), The Stock That Slid 52% In The Last Five Years [Yahoo! Finance News] -14.1%

3/18 Form SEC STAFF LETTER Akebia Therapeutics, -13.1%

11/9 Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease -9.9%

8/2 Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -8.0%

6/4 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -7.6%

3/10 Q4/2019 12/31/2019 EPS -0.790 ZacksConsensus -0.440 ActVsEst (0.350) - Miss -7.6%

8/2 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.8%

3/11 Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $15.00 price target on the stock, down previously from $16.00. -6.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day